<DOC>
	<DOCNO>NCT02663687</DOCNO>
	<brief_summary>This trial look gain information safety tolerability investigational treatment ( SHP623 ) healthy adult volunteer . This study also collect pharmacokinetic data ( body absorb break study drug ) .</brief_summary>
	<brief_title>Phase 1 Study Assess Safety , Tolerability , Pharmacokinetics Recombinant Human C1 Esterase Inhibitor Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>1 . Must consider healthy . Healthy status define absence evidence active chronic disease 2 . Male , nonpregnant , nonlactating female , agree comply applicable contraceptive requirement protocol , females nonchildbearing potential . 3 . Body mass index 18.0 30.0 kg/m2 inclusive body weight &gt; 50 kg ( 110 lbs. ) . This inclusion criterion assess first screen visit . 4 . Hemoglobin â‰¥12.0g/ld . 1 . Have history allergic reaction C1 INH product ( e.g . C1 Inhibitor [ Human ] , Berinert [ C1 Estrace Inhibitor ( Human ) ] C1 estrace [ recombinant ] 2 . Known history alcohol substance abuse within last year . 3 . Donation blood blood product within 60 day prior receive investigational product . 4 . Current use medication except hormonal replacement therapy , hormonal contraceptive occasional use overthecounter nonsteroidal antiinflammatory drug ( NSAID ) acetaminophen . 5 . Have history hypercoagulability predisposition thrombotic event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>